NASDAQ:CCCC C4 Therapeutics Q4 2025 Earnings Report $2.98 -0.05 (-1.65%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.02 +0.04 (+1.17%) As of 09/25/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast C4 Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS -$0.43Beat/MissBeat by +$0.25One Year Ago EPSN/AC4 Therapeutics Revenue ResultsActual Revenue$11.02 millionExpected Revenue$4.48 millionBeat/MissBeat by +$6.54 millionYoY Revenue GrowthN/AC4 Therapeutics Announcement DetailsQuarterQ4 2025Date2/26/2026TimeBefore Market OpensConference Call DateThursday, February 26, 2026Conference Call Time7:00AM ETUpcoming EarningsC4 Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) C4 Therapeutics Earnings HeadlinesCemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma StudySeptember 26 at 12:43 PM | rttnews.comC4 Therapeutics, Inc. Presents New Biomarker Data from Cemsidomide Phase 1 Trial With Dexamethasone and Phase 1b Trial With Elranatamab in Relapsed/Refractory Multiple MyelomaSeptember 25 at 11:40 AM | marketscreener.comMThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 27 at 1:00 AM | Chaikin Analytics (Ad)C4 Therapeutics presenta i dati sui biomarcatori del trial di cemsidomideSeptember 25 at 11:40 AM | it.investing.comC4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory ...September 25 at 11:40 AM | markets.businessinsider.comC4 Therapeutics Reports Phase 1 Cemsidomide Biomarker Data Showing T-Cell Activation and Advances Elranatamab Combination TrialSeptember 25 at 7:31 AM | quiverquant.comQSee More C4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email. Email Address About C4 TherapeuticsC4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to recruit the body’s natural protein-disposal system to remove specific proteins rather than simply inhibit their activity. C4 Therapeutics develops its drug candidates through its proprietary TORPEDO platform, which is intended to identify and optimize small-molecule degraders for challenging biological targets. Its research and development programs have included investigational therapies for cancer, including candidates designed to target proteins involved in tumor growth and survival, such as KRAS G12C and BRD9. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics conducts research and clinical-development activities primarily in the United States. The company has also pursued strategic collaborations with larger pharmaceutical companies to advance targeted protein-degradation research and potential therapies.View C4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
